Fennec Provides Business Update and Announces First Quarter 2018 Financial Results Read more about Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
Raghuram Selvaraju, Ph.D Raghuram Selvaraju, Ph.D HC Wainwright rselvaraju@hcwresearch.com 212-916-3966
David Nierengarten, Ph.D. David Nierengarten,Ph.D. Wedbush David.Nierengarten@wedbush.com 415-274-6862
Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™ Read more about Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™
Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results Read more about Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK Read more about Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK
Fennec Announces Closing of Public Offering Read more about Fennec Announces Closing of Public Offering
Fennec Announces Pricing of Public Offering Read more about Fennec Announces Pricing of Public Offering
Fennec Announces Proposed Public Offering of Common Shares Read more about Fennec Announces Proposed Public Offering of Common Shares
Fennec Provides Business Update And Reports Third Quarter 2017 Results Read more about Fennec Provides Business Update And Reports Third Quarter 2017 Results
